Allred Capital Management’s AYTU BioPharma AYTU Stock Holding History

Allred Capital Management’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6,250	Closed	-$23.6K	–	157
2022 Q4	$23.6K	Buy	6,250 +1,000	+19%	+$3.77K	0.01%	151
2022 Q3	$19K	Buy	5,250 +4,418	+531%	+$33.5K	0.01%	149
2022 Q2	$11K	Buy	+832	New	+$10.6K	0.01%	156
2021 Q2	–	Sell	-136	Closed	-$20.7K	–	234
2021 Q1	$20.7K	Buy	+136	New	+$21.6K	0.01%	535

Other funds holding AYTU

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Allred Capital Management's AYTU Position: Q1 2023 in Review

Allred Capital Management sold out of AYTU BioPharma (AYTU) in Q1 2023, closing a stake of 6,250 shares — an estimated $23.6K sold.

Allred Capital Management first reported a position in AYTU in Q1 2021 and held it in 4 quarters. The position peaked at $23.6K in Q4 2022. 21 funds tracked by Wall St. Rank hold AYTU as of Q1 2023.

Allred Capital Management reported no remaining AYTU BioPharma position as of Q1 2023 after selling out during the quarter.
Allred Capital Management sold 6,250 AYTU BioPharma shares in Q1 2023, an estimated $23.6K.
Allred Capital Management first reported a position in AYTU BioPharma in Q1 2021 and held it in 4 quarters.
Allred Capital Management's AYTU BioPharma position peaked at $23.6K in Q4 2022.
21 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2023.

Based on Allred Capital Management's 13F filing for Q1 2023, filed 10 May 2023.